J.P. Morgan Sticks to Its Sell Rating for GlaxoSmithKline (GSK)
J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40.
Cure for cancer? UK scientists are creating a vaccine that could stop disease up to 20 years early
Pharmaceutical giant GSK and the University of Oxford are collaborating on developing a cancer vaccine that aims to detect ...
FierceBiotech4d
GSK offers up to £50M to conduct cancer vaccine research with the University of Oxford
British pharma giant GSK is heading back to school, pledging up to 50 million pounds sterling (about $62.4 million) to work ...
MM&M10h
Takeda CEO Christophe Weber to retire in 2026, Julie Kim to succeed him
Takeda CEO Christophe Weber announced he will step down in 2026 and be replaced by Julie Kim, president of Takeda’s U.S.
GSK and Oxford researchers to create cancer vaccine to stop disease developing
GSK will invest up to £50 million in the new project, which could inform future development of cancer vaccines.
American Association of Individual Investors2d
Why Zentalis Pharmaceuticals, Inc.’s (ZNTL) Stock Is Down 21.25%
Zentalis Pharmaceuticals, Inc.’s ZNTL share price has dipped by 21.25%, which has investors questioning if this is right time ...
pharmaphorum2d
Pharma holds it breath for ’25 as the sun shines on JP Morgan conference
The word on San Francisco’s famously hilly streets is that big pharma is ready to go shopping in 2025, following a flurry of ...
FiercePharma1d
Amid more drug-price scrutiny, biopharma companies largely keep their January hikes in check
As more United States drug price changes have come to light this month, it remains clear that companies are tamping down ...
Pulmonary Fibrosis Clinical Trial Pipeline Appears Robust With 110+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
The pulmonary fibrosis market is driven by the increasing prevalence of pulmonary fibrosis, especially idiopathic pulmonary fibrosis (IPF), among the aging population, which boosts demand for ...
New cancer vaccine will 'stop disease before it takes hold'
The partnership between the pharmaceutical giant and the university aims to create a vaccine or vaccines which target cells ...
American Association of Individual Investors1d
Which Is a Better Investment, Ionis Pharmaceuticals, Inc. or PTC Therapeutics, Inc. Stock?
Learn more about whether Ionis Pharmaceuticals, Inc. or PTC Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.